Cooperative Agreement NU51IP000858

This is a Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention program (CFDA 93.326). The award, valued at $18,893,037, was made to Beth Israel Deaconess Medical Center, Inc. (Bidmc) for a prospective observational study of respiratory virus epidemiology in the Greater Boston area. The study will span 5 years, from Aug 1, 2024 to Jul 31, 2029....

This federal Cooperative Agreement award was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The total award amount is $1,171,832.00, with a performance period from December 24, 2024 to November 30, 2029. The purpose of this award is to leverage systems biology approaches to identify novel correlates of protection and immune persistence beyond neutralizing antibodies for influenza virus...

This $2,400,000 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health program (CFDA 93.421) is aimed at building capacity within governmental, non-governmental, tribal, and academic organizations to deliver essential public health services. The primary awardee, the National Alliance of State & Territorial AIDS Directors...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $146,922 to Emory University to conduct research on factors that influence the efficiency of influenza A virus (IAV) infection through different modes of exposure. The project aims to examine the relationship between the intensity of IAV exposure (via intranasal inoculation or aerosol) and the diversity of...

The National Health Laboratory Service (NHLS) in South Africa was awarded a $6,000,000 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Federal Grant Program "Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security" (CFDA 93.318). This 5-year award, effective September 1, 2024, supports NHLS's work in collaborative research on influenza and other respiratory pathogens in South...

This $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The key goals are to: Assemble and characterize SAPNs functionalized with highly conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), on the external surface, and...

This Cooperative Agreement award, funded by the Centers for Disease Control and Prevention (CDC) under the Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention program (CFDA 93.326), provides $904,564 to the Indiana Department of Health (IDOH) from August 1, 2024 to July 31, 2029. The purpose of this award is to enhance the capacity of public health agencies in Indiana to effectively detect, respond, prevent and control known and emerging...

The District of Columbia Department of Health (DC Health) was awarded a $2,130,996 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) to support epidemiology and laboratory capacity for prevention and control of emerging infectious diseases in the National Capital Region. The award period runs from Aug 1, 2024 to Jul 31, 2029. The funding will enable DC Health and its Public Health Laboratory to enhance...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to generate high-resolution profiles of influenza virus-immune dynamics during natural infection in humans. The $1,352,292 award, effective from February 1, 2025 to January 31, 2030, will support a multidisciplinary team of experimentalists and computational modelers at the University of Illinois to: (1) identify...

This Cooperative Agreement award, issued by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323), provides $1,499,856.00 to the University of Rochester to support the "TRUSTED SCHOOL MESSENGERS PROMOTING NON-MANDATED VACCINATION" project. The objective of this multi-year (Sep 2024 - Sep 2027) effort is to enhance public health infrastructure for detecting, responding to, preventing, and...